Welcome to our dedicated page for Spectral AI news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. (Nasdaq: MDAIW for its redeemable warrants) is a Dallas-based predictive AI company focused on medical diagnostics in wound care, with initial applications in burn treatment. Company news updates center on the development, clinical use, and regulatory progress of its DeepView System, a non-invasive device and software platform that combines multispectral imaging with proprietary AI algorithms to assess burn wound healing potential.
News coverage for Spectral AI frequently includes announcements about the DeepView System’s role at major burn conferences, such as the British Burn Association, European Burns Association, and regional U.S. burn meetings. These reports describe presentations and posters on topics like AI-enhanced multispectral imaging, real-world burn healing studies, reader studies evaluating clinicians’ ability to detect non-healing wounds, and patient experience with AI-based imaging in burn consultations.
Investors and healthcare professionals can also find updates on Spectral AI’s financial results, including research and development revenue tied to its BARDA Project BioShield contract, cash position, and financing activities that support ongoing DeepView development. Regulatory milestones, such as the submission of a De Novo 510(k) marketing clearance application to the U.S. Food and Drug Administration for DeepView’s use in burn care settings, are another recurring theme in the company’s news releases.
By following Spectral AI news, readers can track how the company reports progress on its AI-driven DeepView technology, its participation in clinical and professional forums, and its efforts to position DeepView as a predictive diagnostic tool in burn and wound care.
Spectral AI's (NASDAQ: MDAI) DeepView® System has achieved a remarkable 95.3% accuracy in burn healing assessment, as published in the prestigious Burns journal. The multi-center clinical study validates the system's effectiveness in using AI-driven multi-spectral imaging to predict burn healing potential across diverse clinical settings.
The technology enables clinicians to make earlier, more informed decisions about healing time and surgical requirements, potentially improving patient outcomes. This publication in Burns, a leading peer-reviewed medical journal of the International Society for Burn Injuries, represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment.
Spectral AI (NASDAQ: MDAI), a company specializing in AI-driven DeepView® System for burn healing prediction through multi-spectral imaging and AI algorithms, has announced its Q1 2025 earnings release schedule. The company will report its financial results for the quarter ending March 31, 2025, on Tuesday, May 13, 2025, after market close.
A conference call to discuss the results will be held at 5:00 pm Eastern Time. Investors can participate by dialing 833-630-1956 (U.S.) or 412-317-1837 (International). A simultaneous webcast will be available through the Events & Presentations section of Spectral AI's Investor Relations website.
Spectral AI (NASDAQ: MDAI) showcased its DeepView® System at the American Burn Association annual meeting in Phoenix, Arizona. The event, attended by over 2,200 burn care professionals, highlighted significant achievements in burn wound assessment technology.
Key findings presented by Leslie Tan of Newcastle Burns Centre revealed the DeepView System's impressive 95% accuracy rate in predicting burn wound healing potential within 21 days. The technology received additional recognition when Zeeshan Sheikh of Wythenshawe Hospital won Best in Category for his presentation on patient experience with AI-Enhanced Multispectral Imaging.
The DeepView System, which combines multi-spectral imaging with AI algorithms, is currently operational in several NHS hospitals in the United Kingdom. Newcastle Burn Centre, treating approximately 500 burn patients annually, became the first institution globally to conduct an independent evaluation of this technology.
Spectral AI (NASDAQ: MDAI) reported its Q4 and full-year 2024 financial results, highlighting significant achievements in its AI-driven wound care diagnostics business. The company's research and development revenue reached $30 million in 2024, marking a 63.5% increase from 2023, primarily driven by their BARDA PBS contract.
Key financial metrics include Q4 2024 R&D revenue of $7.6 million and a gross margin of 44.0%. The company reported a full-year net loss of $15.3 million. As of December 31, 2024, cash stood at $5.2 million, with additional Q1 2025 financing of $11.2 million through debt and equity.
Notable achievements include successful results from the US Burn Validation Study, where their DeepView System demonstrated 86.6% sensitivity in identifying non-healing tissue, significantly outperforming burn physicians' 40.8%. The company plans FDA submission in Q2 2025 and anticipates first commercial revenue in H2 2025.
Spectral AI (NASDAQ: MDAI) has secured up to $15 million in debt financing from Avenue Venture Opportunities Fund II, with an initial draw of $8.5 million. The company also raised $2.7 million in equity financing from institutional and existing investors.
The financing agreement spans three years with an interest-only payment period of 15-24 months, depending on milestone achievement. A second financing tranche, contingent on FDA clearance of the DeepView System, includes an additional $6.5 million in debt and a $7.0 million equity raise.
The deal includes warrant coverage of 8.5% with an exercise price of $1.80 per share, and a six-month market standstill period. With total cash now exceeding $14 million, Spectral AI aims to accelerate the U.S. commercialization of its AI-driven DeepView System, designed to predict burn healing potential using multi-spectral imaging and AI algorithms.
Spectral AI (NASDAQ: MDAI), developer of the AI-driven DeepView® System for burn healing prediction, announced that its subsidiary Spectral IP (to be renamed SIM IP) has filed a registration statement with the SEC for a planned IPO spinoff. The subsidiary has applied to list on the Nasdaq Capital Market under the symbol 'SMIP'.
The DeepView® System, which received FDA Breakthrough Device Designation in 2018, utilizes multi-spectral imaging and AI algorithms. Dominari Securities will serve as the lead underwriter, with Revere Securities as co-underwriter. The number of shares and price range are yet to be determined.
The registration statement (File Number: 333-285935) was filed on March 20, 2025. The offering will proceed only after SEC effectiveness and will be made available through a prospectus.
FAQ
What is the current stock price of Spectral AI (MDAIW)?
